Anupam Rasayan India Ltd. · NSE:ANURAS
Anupam Rasayan India — Q1 FY24 Earnings Presentation
24 slides from Anupam Rasayan India's earnings presentation, Aug 1, 2023
Slide 1: Investor Presentation cover letter to stock exchanges
ANUPAM RASAYAN INDIA LTD. R ARILSLDSTX20230801046 Date: August 01, 2023 To, To, BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, ‘Exchange Plaza’, C-1, Block-G, Dalal Street, Bandra Kurla Complex Mumbai -400001, India Bandra (East), Mumbai 400051, India SCRIP CODE: 54
Slide 2: Anupam Rasayan India Limited Investor Presentation Q1FY24
ANUPAM RASAYAN INDIA LIMITED INVESTOR PRESENTATION BSE: 543275 | NSE: ANURAS | ISIN: INE930P01018 Q1FY24 ©2020 – Anupam Rasayan India Limited, All Rights Reserved. August 2023
Slide 3: Financials and Operational Updates
FINANCIALS AND OPERATIONAL UPDATES
Slide 4: Quarterly Financial Highlights
Quarterly Financial Highlights Consolidated Total Revenue was Consolidated EBITDA (Incl. Other Consolidated PAT stood at ₹ 523 ₹3,988 Mn; Y-o-Y growth of 19% Revenue) was ₹ 1,138 Mn.; margin Mn., margin stands at 13% stands at 29% Standalone Total Revenue was Standalone EBITDA (Incl. Other Standalon
Slide 5: Managing Director's Message
Managing Director’s Message Mr. Anand S Desai “I am delighted at the consistent growth momentum of the Company against a M A N A G I N G D I R E C TO R challenging industry backdrop. Our consolidated revenue witnessed robust 19% Y-o-Y growth at Rs 3,988 Mn. While the falling prices of commodity agro
Slide 6: Operational Updates
Operational Updates • New LOI’s Signed – In Q1FY24, we have signed LOI’s worth ₹40,660 Mn with Japanese and American MNCs for niche life sciences and specialty chemical molecules. These LOI’s demonstrates the increasing confidence of global MNCs in our technical capabilities and sustainable supply c
Slide 7: Strong Order Book – Recent LOI/Contracts Signed
Strong Order Book – Recent LOI/Contracts Signed Signing Quarter Segment Customer LOI/Contract Tenor (Years) Value(₹ Crores) Multinational Life Science Q1FY22 Life Science LOI 5 ₹1,100 Company Q1FY22 Life Science Two Multinational Companies Contract 5 ₹540 European Multinational Q2FY22 Life Science C
Slide 8: Consolidated Profit & Loss Summary
QUARTERLY FINANCIALS Consolidated Profit & Loss Summary (All amounts are in ₹ Mn) Q1FY24 Q1FY23 INCOME Revenue from Operations 3,864 3,436 Other Income 124 (93) Total Revenue 3,988 3,343 Total Revenue Growth (%) 19% EXPENSES: Cost of Raw Materials Consumed 1,630 1,376 Gross Profit 2,234 2,060 Gross
Slide 9: Standalone Profit & Loss Summary
QUARTERLY FINANCIALS Standalone Profit & Loss Summary (All amounts are in ₹ Mn) Q1FY24 Q1FY23 INCOME Revenue from Operations 2,885 3,098 Other Income 99 (127) Total Revenue 2,983 2,971 Total Revenue Growth (%) 0.39% EXPENSES: Cost of Raw Materials Consumed 1,100 1,128 Gross Profit 1,785 1,970 Gross
Slide 10: Our Business
OUR BUSINESS
Slide 11: About Anupam
About Anupam COMPANY AT A GLANCE Established Custom Synthesis player Specializes in multi-step Catering to globally relevant Strong supply chain with backward with 39 years of track record synthesis undertaking complex chemical & agrochemical integrated facilities chemical reactions to produce key c
Slide 12: Business Verticals & Customers
Business Verticals & Customers BUSINESS VERTICALS OVERVIEW FEW OF OUR TOP GLOBAL CLIENTS Life Science Related Other Specialty Specialty Chemicals Chemicals Agrochemicals Specialty Pigments (including Crop Protection) Manufacturing agro intermediates and agro active ingredients (insecticides, Special
Slide 13: Making a Mark Globally
Making a Mark Globally MANUFACTURING CLIENTELE UNITS IN INDIA GLOBALLY (In Nos.) (In Nos.) 6* 71* REVENUE BY GEOGRAPHY EUROPE 26% EUROPE 30% EUROPE 28% INDIA 44% INDIA 36% INDIA 42% SINGAPORE 11% SINGAPORE 11% FY21 SINGAPORE 10% FY22 JAPAN 12% FY23 JAPAN 16% JAPAN 15% CHINA 4% CHINA 4% CHINA 4% NORT
Slide 14: Evolution of Anupam
Evolution of Anupam Phase I-Inception Phase II- The Acceleration • Started working with • Raised ₹5,000 mn. • Fast growing • Formed • Started supplying • Awarded ‘Green • Commercialized 2 through QIP Specialty Chemical partnership firm to Syngenta Innovation Award’ more Adama Manufacturer with “Anup
Slide 15: Strong Manufacturing and R&D Capabilities
Strong Manufacturing and R&D Capabilities Manufacturing prowess R&D Competencies • DSIR recognized R&D center with a team of 88 R&D professionals ~27,200 MT Manufacturing Capacity, spread over 6 manufacturing facilities • Expertise in executing complex chemistries & multi step synthesis • Deployed f
Slide 16: Growth Drivers
Growth Drivers Growth of Product Execution of Signed LOIs Expansion in Portfolio and Contracts Fluorination chemistry ANUPAM RASAYAN INDIA LIMITED | 15
Slide 17: Growth of Product Portfolio
Growth Of Product Portfolio NUMBER OF MOLECULES IN NUMBER OF MOLECULES TO R&D AND PILOT BE COMMERCIALISED IN FY24 90+ 10+ New Strategic Custom Development Products under pipeline to be manufactured by Anupam in India: Agro: • Established Active Ingredients of originators which are currently being ma
Slide 18: Anupam – Tanfac Integration
Anupam – Tanfac Integration Anupam acquired ~26% stake in Tanfac for ~₹1,530M in May'22 Backward integration with Tanfac to secure KSM Uninterrupted access to key raw materials (HF and KF) for fluorination chemistry Only Indian Producer of manufacturer of Leading producer fluorinated niche molecules
Slide 19: Expansion in Fluorination Chemistry
Expansion in Fluorination chemistry Details of Few Molecules out of 14 Identified Segment Revenue Focused Segments Molecules End Application Customer Potential Product A Elastomer US MNC Polymers $ 40 – 70 Mn. Semiconductor/Flame Product B Japanese MNC Retardant Product X/Y Cardio/Anti-viral Indian
Slide 20: Experienced Leadership & Deep Technical Talent Pool
Experienced Leadership & Deep Technical Talent Pool Experienced management team Our R&D talent pool Mr. Anand Desai Ms. Mona A Desai Image here Managing Director Over 30 years of experience in Image here Vice- Chairman & Whole- Time Director 88+ 175+ chemicals industry associated Over 20 years of ex
Slide 21: Expanded Business Development Team
Expanded Business Development Team Europe Mr. Thierry Baumlin Mr. Pierre Joris Key Account Manager – Crop Business Advisor – Specialty Protection Fluoro Chemicals 30 years+ of experience in 30 years+ of experience in Chemicals industry; former strategy Chemicals industry; former SBU head procurement
Slide 22: Board of Directors
Board of Directors DR. KIRAN C PATEL MR. ANAND S DESAI MS. MONA A DESAI MR. MILAN THAKKAR CHAIRMAN & MANAGING DIRECTOR VICE-CHAIRMAN & NON-EXECUTIVE DIRECTOR NON-EXECUTIVE DIRECTOR WHOLE-TIME DIRECTOR • Associated with the company for past • Over 30 years of experience in • Over 20 years of experien
Slide 23: Safe Harbor
Safe Harbor Certain statements in this presentation concerning our future growth prospects are forward looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company's results may
Slide 24: Thank You
THANK YOU CONTACT US: MR. VISHAL THAKKAR MR. RAVISH CHAUDHARY Anupam Rasayan India Ltd. investors@anupamrasayan.com MR. RAHUL THKUR MR. DIWAKAR PINGLE EY Investor Relations Rahul.thakur@in.ey.com diwakar.pingle@ey.com CORPORATE OFFICE 10th Floor, Icon Rio, Behind Icon Business Centre, Dumas Road, Su